课题基金 / 基金详情

DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS

DOUBLE-BLIND PHASE II STUDY OF MULTIPLE DOSES OF PALIFERMIN (RHUKGF) FOR AIDS
多剂量 Palifermin (RHUKGF) 治疗艾滋病的双盲 II 期研究
批准号：
7951580
负责人：
RONALD T. MITSUYASU
金额：
$4.99万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-04-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7951580
关键词：
Acquired Immunodeficiency SyndromeCD4 Lymphocyte CountClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDoseDouble-Blind MethodFundingGrantInstitutionPhase II Clinical TrialsPlacebosResearchResearch PersonnelResourcesSourceTimeTreatment ProtocolsUnited States National Institutes of Healthkeratinocyte growth factor

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 证明在第12周时间点，与安慰剂相比，帕利弗明3种给药方案之一的绝对CD 4+淋巴细胞计数升高幅度更大。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To demonstrate a greater rise in absolute CD4+ lymphocyte count with one of the three dose regimens of palifermin compared with placebo at the week 12 time point.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)